Richard H Tran1, Ahmed Aldemerdash2, Patricia Chang3, Carla A Sueta3, Brystana Kaufman4, Josephine Asafu-Adjei5, Orly Vardeny6, Eliza Daubert7, Khalid A Alburikan2, Anna M Kucharska-Newton4, Sally C Stearns4, Jo E Rodgers8. 1. Pharmaceutical Product Development, Morrisville, North Carolina. 2. Clinical Pharmacy, King Saudi University, Riyadh, Saudi Arabia. 3. UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 4. Gillings School of Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 5. Gillings School of Public Health, Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 6. Minneapolis VA Center for Chronic Disease Outcomes Research and University of Minnesota Medical School, Minneapolis, Minnesota. 7. United Therapeutics, Durham, North Carolina. 8. UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Abstract
BACKGROUND: Modification of guideline-directed medical therapy (GDMT) in hospitalized patients with heart failure (HF) has not been extensively evaluated. METHODS: The community surveillance arm of the Atherosclerosis Risk in Communities Study identified 6959 HF hospitalizations from 2005-2011. Predictors of GDMT modification and survival were assessed using multivariable logistic regression and Cox proportional hazards models. RESULTS: For 5091 hospitalizations, patient mean age was 75 years, 53% were female, 69% were white, and 81% had acute decompensated heart failure (ADHF). Regarding ejection fraction (EF), 31% of patients had HF with reduced EF (HFrEF), 24% had HF with preserved EF (HFpEF), and 44% were missing EF values. At admission, 52% of patients received angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), 66% β-blockers (BBs), 9% aldosterone-receptor antagonists, 16% digoxin, 10% hydralazine, and 29% nitrates. Modification of GDMT occurred in up to 23% of hospitalizations. Significant predictors of GDMT initiation included ADHF and HFrEF; discontinuation of medications was observed with select comorbidities. In HFrEF, initiation of any GDMT was associated with reduced 1-year all-cause mortality (adjusted hazard ratio [HR] 0.41, 95% confidence interval [CI] 0.23-0.71) as was initiation of ACEI/ARBs, BBs, and digoxin. Discontinuation of any therapy versus maintaining GDMT was associated with greater mortality (HR 1.30, 95% CI 1.02-1.66). Similar trends were observed in HFpEF. CONCLUSIONS: Our study suggests that GDMT initiation is associated with increased survival, and discontinuation of therapy is associated with reduced survival in hospitalized patients with HF. Future studies should be conducted to confirm the impact of GDMT therapy modification in this population.
BACKGROUND: Modification of guideline-directed medical therapy (GDMT) in hospitalized patients with heart failure (HF) has not been extensively evaluated. METHODS: The community surveillance arm of the Atherosclerosis Risk in Communities Study identified 6959 HF hospitalizations from 2005-2011. Predictors of GDMT modification and survival were assessed using multivariable logistic regression and Cox proportional hazards models. RESULTS: For 5091 hospitalizations, patient mean age was 75 years, 53% were female, 69% were white, and 81% had acute decompensated heart failure (ADHF). Regarding ejection fraction (EF), 31% of patients had HF with reduced EF (HFrEF), 24% had HF with preserved EF (HFpEF), and 44% were missing EF values. At admission, 52% of patients received angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), 66% β-blockers (BBs), 9% aldosterone-receptor antagonists, 16% digoxin, 10% hydralazine, and 29% nitrates. Modification of GDMT occurred in up to 23% of hospitalizations. Significant predictors of GDMT initiation included ADHF and HFrEF; discontinuation of medications was observed with select comorbidities. In HFrEF, initiation of any GDMT was associated with reduced 1-year all-cause mortality (adjusted hazard ratio [HR] 0.41, 95% confidence interval [CI] 0.23-0.71) as was initiation of ACEI/ARBs, BBs, and digoxin. Discontinuation of any therapy versus maintaining GDMT was associated with greater mortality (HR 1.30, 95% CI 1.02-1.66). Similar trends were observed in HFpEF. CONCLUSIONS: Our study suggests that GDMT initiation is associated with increased survival, and discontinuation of therapy is associated with reduced survival in hospitalized patients with HF. Future studies should be conducted to confirm the impact of GDMT therapy modification in this population.
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: Circulation Date: 2013-06-05 Impact factor: 29.690
Authors: Alan Maisel; Yang Xue; Dirk J van Veldhuisen; Adriaan A Voors; Tiny Jaarsma; Peter S Pang; Javed Butler; Bertram Pitt; Paul Clopton; Rudolf A de Boer Journal: Am J Cardiol Date: 2014-06-19 Impact factor: 2.778
Authors: Ali Ahmed; Robert C Bourge; Gregg C Fonarow; Kanan Patel; Charity J Morgan; Jerome L Fleg; Inmaculada B Aban; Thomas E Love; Clyde W Yancy; Prakash Deedwania; Dirk J van Veldhuisen; Gerasimos S Filippatos; Stefan D Anker; Richard M Allman Journal: Am J Med Date: 2013-11-18 Impact factor: 4.965
Authors: Gregg C Fonarow; Nancy M Albert; Anne B Curtis; Wendy Gattis Stough; Mihai Gheorghiade; J Thomas Heywood; Mark L McBride; Patches Johnson Inge; Mandeep R Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh; Clyde W Yancy Journal: Circulation Date: 2010-07-26 Impact factor: 29.690
Authors: Gregg C Fonarow; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young Journal: J Am Coll Cardiol Date: 2008-07-15 Impact factor: 24.094
Authors: Adrian F Hernandez; Xiaojuan Mi; Bradley G Hammill; Stephen C Hammill; Paul A Heidenreich; Frederick A Masoudi; Laura G Qualls; Eric D Peterson; Gregg C Fonarow; Lesley H Curtis Journal: JAMA Date: 2012-11-28 Impact factor: 56.272
Authors: Lauren G Gilstrap; Gregg C Fonarow; Akshay S Desai; Li Liang; Roland Matsouaka; Adam D DeVore; Eric E Smith; Paul Heidenreich; Adrian F Hernandez; Clyde W Yancy; Deepak L Bhatt Journal: J Am Heart Assoc Date: 2017-02-11 Impact factor: 5.501
Authors: Terry Lee; Alessandro Cau; Matthew Pellan Cheng; Adeera Levin; Todd C Lee; Donald C Vinh; Francois Lamontagne; Joel Singer; Keith R Walley; Srinivas Murthy; David Patrick; Oleksa G Rewa; Brent W Winston; John Marshall; John Boyd; Karen Tran; Andre C Kalil; Russell Mcculoh; Robert Fowler; James M Luther; James A Russell Journal: CJC Open Date: 2021-04-06
Authors: James A Russell; John C Marshall; Arthur Slutsky; Srinivas Murthy; Dave Sweet; Terry Lee; Joel Singer; David M Patrick; Bin Du; Zhiyong Peng; Matthew Cheng; Kevin D Burns; Michael O Harhay Journal: BMJ Open Date: 2020-12-07 Impact factor: 2.692
Authors: Ahmad Jabri; Laith Alhuneafat; Zaid Shahrori; Hani Hamade; Farhan Nasser; Abdallah Rayyan; Mohammed Mhanna; Ahmad Al Abdouh; Faris Haddadin; Kathir Balakumaran Journal: J Clin Med Res Date: 2022-08-27
Authors: Marat Fudim; Sabina Sayeed; Haolin Xu; Roland A Matsouaka; Paul A Heidenreich; Eric J Velazquez; Clyde W Yancy; Gregg C Fonarow; Adrian F Hernandez; Adam D DeVore Journal: Circ Heart Fail Date: 2020-04-06 Impact factor: 8.790